Variation of hormonal receptor, pS2, c-erbB-2 and GSTi contents in breast carcinomas under tamoxifen: a study of 74 cases
1996

Hormonal Receptor Changes in Breast Cancer Under Tamoxifen

Sample size: 74 publication Evidence: moderate

Author Information

Author(s): I Soubeyran, N Quenell, L Mauriac, M Durand, F Bonichon, J-M Coindre

Primary Institution: Institut Bergonie

Hypothesis

What are the changes in hormonal receptor content in breast carcinomas after tamoxifen treatment?

Conclusion

Tamoxifen treatment significantly decreased estrogen and progesterone receptor levels while increasing pS2 and GSTi levels in breast cancer patients.

Supporting Evidence

  • Estrogen receptors decreased in 60 cases after tamoxifen treatment.
  • Progesterone receptors decreased in 44 cases after treatment.
  • GSTi and pS2 levels increased significantly in 43 and 41 cases respectively.

Takeaway

This study looked at how a medicine called tamoxifen changes certain proteins in breast cancer cells. It found that tamoxifen lowers some important proteins but raises others.

Methodology

The study involved 74 post-menopausal patients treated with tamoxifen for 5 months, with biopsies analyzed for hormonal receptors and related proteins.

Potential Biases

Potential biases due to the retrospective nature of the study and the selection of patients.

Limitations

The study is retrospective and may have selection biases.

Participant Demographics

Post-menopausal women with primary non-metastatic invasive ductal breast carcinomas.

Statistical Information

P-Value

P<10-4

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication